A conditional form of Bruton's tyrosine kinase is sufficient to activate multiple downstream signaling pathways via PLC Gamma 2 in B cells
- PMID: 11410123
- PMCID: PMC32313
- DOI: 10.1186/1471-2172-2-4
A conditional form of Bruton's tyrosine kinase is sufficient to activate multiple downstream signaling pathways via PLC Gamma 2 in B cells
Abstract
Background: Bruton's tyrosine kinase (Btk) is essential for B cell development and function. Mutations of Btk elicit X-linked agammaglobulinemia in humans and X-linked immunodeficiency in the mouse. Btk has been proposed to participate in B cell antigen receptor-induced signaling events leading to activation of phospholipase C-gamma2 (PLCgamma2) and calcium mobilization. However it is unclear whether Btk activation is alone sufficient for these signaling events, and whether Btk can activate additional pathways that do not involve PLCgamma2. To address such issues we have generated Btk:ER, a conditionally active form of the kinase, and expressed it in the PLCgamma2-deficient DT40 B cell line.
Results: Activation of Btk:ER was sufficient to induce multiple B cell signaling pathways in PLCgamma2-sufficient DT40 cells. These included tyrosine phosphorylation of PLCgamma2, mobilization of intracellular calcium, activation of extracellular signal-regulated kinase (ERK) and c-Jun NH2-terminal kinase (JNK) mitogen-activated protein kinase (MAPK) pathways, and apoptosis. In DT40 B cells deficient for PLCgamma2, Btk:ER activation failed to induce the signaling events described above with the consequence that the cells failed to undergo apoptosis.
Conclusions: These data suggest that Btk:ER regulates downstream signaling pathways primarily via PLCgamma2 in B cells. While it is not known whether activated Btk:ER precisely mimics activated Btk, this conditional system will likely facilitate the dissection of the role of Btk and its family members in a variety of biological processes in many different cell types.
Figures





Similar articles
-
Bruton's tyrosine kinase is essential for hydrogen peroxide-induced calcium signaling.Biochemistry. 2001 Jul 10;40(27):8085-91. doi: 10.1021/bi0100788. Biochemistry. 2001. PMID: 11434777
-
Four tyrosine residues in phospholipase C-gamma 2, identified as Btk-dependent phosphorylation sites, are required for B cell antigen receptor-coupled calcium signaling.J Biol Chem. 2001 Oct 19;276(42):38595-601. doi: 10.1074/jbc.M103675200. Epub 2001 Aug 15. J Biol Chem. 2001. PMID: 11507089
-
Reconstitution of Btk signaling by the atypical tec family tyrosine kinases Bmx and Txk.J Biol Chem. 1999 May 7;274(19):13577-85. doi: 10.1074/jbc.274.19.13577. J Biol Chem. 1999. PMID: 10224128
-
Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway.Front Immunol. 2021 Jun 10;12:689472. doi: 10.3389/fimmu.2021.689472. eCollection 2021. Front Immunol. 2021. PMID: 34177947 Free PMC article. Review.
-
Regulation of B lymphocyte development and activation by Bruton's tyrosine kinase.Immunol Res. 2001;23(2-3):147-56. doi: 10.1385/IR:23:2-3:147. Immunol Res. 2001. PMID: 11444380 Review.
Cited by
-
Is there a role for anti-CD20 antibodies in CLL?Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):68-75. doi: 10.1182/hematology.2021000234. Hematology Am Soc Hematol Educ Program. 2021. PMID: 34889417 Free PMC article.
-
PLCγ2 promotes apoptosis while inhibits proliferation in rat hepatocytes through PKCD/JNK MAPK and PKCD/p38 MAPK signalling.Cell Prolif. 2018 Jun;51(3):e12437. doi: 10.1111/cpr.12437. Epub 2018 Feb 11. Cell Prolif. 2018. PMID: 29430764 Free PMC article.
-
Development of a novel Bruton's tyrosine kinase inhibitor that exerts anti-cancer activities potentiates response of chemotherapeutic agents in multiple myeloma stem cell-like cells.Front Pharmacol. 2022 Sep 9;13:894535. doi: 10.3389/fphar.2022.894535. eCollection 2022. Front Pharmacol. 2022. PMID: 36160379 Free PMC article.
-
Requirements for distinct steps of phospholipase Cgamma2 regulation, membrane-raft-dependent targeting and subsequent enzyme activation in B-cell signalling.Biochem J. 2003 Aug 15;374(Pt 1):269-80. doi: 10.1042/BJ20021778. Biochem J. 2003. PMID: 12780340 Free PMC article.
-
Evaluating Acalabrutinib In The Treatment Of Mantle Cell Lymphoma: Design, Development, And Place In Therapy.Onco Targets Ther. 2019 Sep 30;12:8003-8014. doi: 10.2147/OTT.S155778. eCollection 2019. Onco Targets Ther. 2019. PMID: 31686856 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous